Kisspeptin

Kisspeptin refers to KISS1-derived neuropeptides that activate the kisspeptin receptor KISS1R, historically called GPR54. This pathway is a central upstream regulator of gonadotropin-releasing hormone signaling and therefore affects luteinizing hormone, follicle-stimulating hormone, and downstream reproductive hormones. Human genetic studies showed that loss-of-function KISS1R/GPR54 mutations can cause isolated hypogonadotropic hypogonadism and impaired pubertal development, establishing the pathway as biologically important rather than merely experimental ^[1][2]. Small controlled human studies found that kisspeptin-54 and kisspeptin-10 can stimulate reproductive hormone release, with responses varying by sex and menstrual-cycle context ^[3][4]. Clinical research has also evaluated kisspeptin-54 as an oocyte-maturation trigger in supervised IVF settings, including women at high risk of ovarian hyperstimulation syndrome ^[5][6]. Kisspeptin remains a research-focused peptide; these findings should not be read as general medical-use guidance or proof of approval for fertility, hormonal, or sexual-health treatment.

Reproductive-Axis Signaling

Kisspeptin is best supported as an upstream regulator of GnRH and gonadotropin release. Human loss-of-function genetics and receptor studies link KISS1R/GPR54 disruption to impaired puberty and hypogonadotropic hypogonadism ^[1][2].

Human Hormone-Release Studies

Small human pharmacology studies found that kisspeptin-54 increased LH, FSH, and testosterone in men, while kisspeptin-10 responses differed by sex and menstrual-cycle timing ^[3][4]. These are controlled research findings, not dosing guidance.

IVF Trigger Research

In supervised IVF studies, kisspeptin-54 triggered oocyte maturation, including in a phase 2 study of women at elevated ovarian hyperstimulation syndrome risk ^[5][6]. This evidence is specific to monitored reproductive-medicine protocols and should not be generalized outside clinical care.

Neurobehavioral Research

A randomized crossover trial in women with hypoactive sexual desire disorder reported effects on brain-processing and psychometric endpoints ^[7]. This remains early clinical research rather than an approved indication.

Research Use, Not Medical Advice

Kisspeptin content should be interpreted as research information, not as an FDA- or EMA-approved treatment recommendation. Existing human studies were conducted in controlled research or specialist IVF settings ^[3][5][6].

Hormonal Effects Require Caution

Because kisspeptin can stimulate LH, FSH, testosterone, and reproductive-axis signaling, unsupervised use could be inappropriate for people with endocrine, fertility, pregnancy-related, or hormone-sensitive conditions ^[3][4].

IVF Evidence Is Context-Specific

The high-risk IVF study reported no moderate, severe, or critical ovarian hyperstimulation syndrome, but it was a 60-person phase 2 open-label randomized study in a monitored clinical protocol ^[6]. That safety signal should not be treated as broad proof of safety.

Evidence Limits

Most therapeutic evidence is small, specialized, or early phase. Genetic and endocrine studies strongly support mechanism, but clinical outcome evidence remains condition-specific and incomplete ^[1][2][5][7].